US7291391057 - Common Stock
PLIANT THERAPEUTICS INC
NASDAQ:PLRX (4/19/2024, 7:10:29 PM)
After market: 12.52 0 (0%)12.52
+0.33 (+2.71%)
Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. The company is headquartered in South San Francisco, California and currently employs 124 full-time employees. The company went IPO on 2020-06-03. The firm is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. The company focuses in treating fibrosis by inhibiting integrin-mediated activation of transforming growth factor beta (TGF-B). Its lead product candidate, bexotegrast (PLN-74809), is an oral small-molecule, dual-selective inhibitor of avß6 and avB1. Its second product candidate, PLN-1474, is a small-molecule, selective inhibitor of avB1 for treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition to its clinical programs, it is developing additional preclinical integrin-based programs targeting muscular dystrophies. The company is also developing PLN-101095 an oral, dual inhibitor of αvß8 and αvß1 integrins for the treatment of solid tumors. Its clinical programs also include PLN-101325, an allosteric agonistic monoclonal antibody against α7β1 for treatment of muscular dystrophies.
PLIANT THERAPEUTICS INC
260 Littlefield Avenue, Suite 150
South San Francisco CALIFORNIA 94080
P: 16504816770
CEO: Bernard Coulie
Employees: 124
Website: https://pliantrx.com/
Bexotegrast clinical poster selected for featured oral presentation at ATS 2024 Mini Symposium SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE...
Acceptance by European Union and other global health authorities of the pivotal, adaptivePhase 2b/3 trial will significantly shorten bexotegrast’s time to...
Here you can normally see the latest stock twits on PLRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: